GlassScriptPhysician profile
Eric B Zywicki
NPI 1851801443
$6,674.25
in general payments reported to CMS, 2019-2025
35 companies · $2,244 in 2025
The $2,244 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $1,672 · 2023: $1,294 · 2024: $951 · 2025: $2,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,407 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,407.46 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $817.16 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $730.00 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $675.80 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $581.54 | 2022-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $562.05 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $506.12 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $427.86 | 2022-2025 | |
| Lundbeck LLC | $396.13 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $354.95 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $308.09 | 2025 | Cobenfy |
| Tris Pharma INC | $250.42 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Novartis Pharmaceuticals Corporation | $137.58 | 2021 | |
| Sunovion Pharmaceuticals INC. | $123.84 | 2022 | |
| Neurocrine Biosciences, INC. | $99.70 | 2022-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $96.89 | 2022-2024 | Qelbree, Qelbree |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $90.90 | 2021 | |
| Neuronetics, INC. | $57.71 | 2025 | Neurostar Tms Therapy System |
| Taiho Oncology, INC. | $54.76 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $48.66 | 2021-2022 | |
| Astellas Pharma US INC | $38.70 | 2022 | |
| Janssen Biotech, INC. | $37.97 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.35 | 2021 | |
| Rigel Pharmaceuticals, INC. | $24.07 | 2021 | |
| Lilly USA, LLC | $23.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.08 | 2021 | |
| Seagen INC. | $20.38 | 2021 | |
| Global Blood Therapeutics, INC. | $20.09 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.01 | 2025 | Quviviq |
| Emmaus Medical, INC. | $18.77 | 2021 | |
| Emd Serono, INC. | $18.72 | 2021 | |
| Dova Pharmaceuticals | $18.53 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.03 | 2022 | |
| Almatica Pharma LLC | $16.73 | 2024 | Loreev Xr |
| Genzyme Corporation | $15.54 | 2021 | |
| Merck Sharp & Dohme LLC | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Zywicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.